Monoclonal antibody therapy

An increasing number of monoclonal antibodies are either commercially available or available in clinical trials for follicular NHL (Table 53.1).

Single-agent rituximab therapy The treatment paradigm for the approach to indolent B-cell malignancies has been revolutionized by the availability of active monoclonal antibodies and related agents. Rituximab has become an integral component of the therapy of most patients with follicular NHL. The original studies of this chimeric anti-CD20 monoclonal antibody were conducted in patients with relapsed and refractory fol-licular and low-grade NHL. In the pivotal trial including 166 patients treated with a dose of 375 mg/m2

Table 53.1 Unconjugated monoclonal antibodies for follicular NHL

Antibody Target Status

Table 53.1 Unconjugated monoclonal antibodies for follicular NHL

Antibody Target Status

Rituximab

0 0

Post a comment